Filing Flows › Verrica Pharmaceuticals (VRCA) › Q2 2025
Verrica Pharmaceuticals (VRCA) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 12, 2025
Verrica Pharmaceuticals (VRCA) reported revenue of $12.7M for the second quarter 2025 (Q2 2025), +145% from a year earlier and +269% from the quarter before. Operating margin was 11.9%, net earnings $204K (1.6% of revenue).
Verrica Pharmaceuticals, Q2 2025: revenue $12.7M (+145% year over year), operating margin 11.9%, net earnings $204K, operating cash flow −$10.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $12.7M | +269% | +145% |
| Operating profit | $1.5M | — | — |
| Net earnings | $204K | — | — |
| Operating cash flow | −$10.0M | — | — |
What changed
Revenue was $12.7M in Q2 2025, up 145% year over year and up 269% from the previous quarter. License and Collaboration Revenue was the largest line at 64% of revenue. License and Collaboration Revenue added $7.9M year over year (up 2766%), 105% of the total change. Product declined 7%.
Operating profit was $1.5M, a 11.9% margin (up 305.6 points year over year). Total costs fell 45% while revenue rose 145%. Net earnings were $204K. The effective tax rate was 0.0%.
Operating cash flow was −$10.0M. Non-cash charges added back $45K of depreciation and $888K of share-based compensation. Working capital and other items used $11.2M.
Questions
What was Verrica Pharmaceuticals' revenue in the second quarter 2025?
Verrica Pharmaceuticals (VRCA) reported revenue of $12.7M for the second quarter 2025 (Q2 2025), +145% from a year earlier and +269% from the quarter before.
Was Verrica Pharmaceuticals profitable in the second quarter 2025?
Operating profit was $1.5M (11.9% of revenue) and net earnings $204K.